Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Is Johnson & Johnson stock a buy after it announced plans to switch to cornstarch-based baby powder? Is JNJ stock a buy now?

Johnson & Johnson Is Out Of The Talc Game — Is It A Buy Now?

AbbVie

Bristol-Myers

Royalty Pharma

The Oracle of Omaha doesn't like pharma stocks for some reason.

Do Warren Buffett's Recent Moves Spell Doom for This Group of Stocks?

Johnson & Johnson JNJ, -0.87% on Wednesday named former CVS Health Corp. CVS, -1.18% CEO Larry Merlo as non-executive chair designate of its new consumer health company, which the company announced in November. Merlo will assume a board leadership role with the new consumer health company for its planned separation from J&J in 2023.

Johnson & Johnson taps ex-CEO of CVS for board leadership role at new consumer unit

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the appointment of Larry Merlo as Non-executive Chair Designate for the future, listed New Consumer Health Company's Board of Directors. Merlo previously served as President and CEO of CVS Health and brings over 30 years of purpose-driven and transformative health leadership to the Board for the planned new company. As announced in November 2021, the planned separation would create two global leaders – the n

Johnson & Johnson Appoints Larry Merlo as Non-Executive Chair Designate of Planned New Consumer Health Company

Arrowhead Pharmaceuticals

JNJ tends to announce big news at yearly fall conference, which might be a catalyst for partnered Arrowhead Pharmaceuticals this fall. JNJ's collaboration project with Arrowhead could be ready for Phase 3 at any time, potentially triggering future milestone payments.

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Gilead Sciences

Johnson & Johnson is a quintessential dividend growth stock. However, its spinoff plan creates some uncertainties ahead. For investors looking for alternative dividend ideas in the healthcare space, Gilead might appear to be a viable contender.

Gilead Vs. Johnson & Johnson: Who's The Better Dividend Stock?

AstraZeneca

Moderna

Pfizer

Here is a rundown of the top pharmaceutical stocks to know about, ranked by market capitalization: Johnson & Johnson, Pfizer, Eli Lilly, AbbVie

Ups & Downs: Top Pharmaceutical Stocks Post-COVID

Home Depot

JPMorgan Chase & Co

Are these top dividend stocks on your watchlist right now?

Best Stocks To Invest In 2022? 3 Top Dividend Stocks To Watch

Chevron

Coca-Cola

Two of these stocks together generate more than $1.6 billion in annual dividend income for Berkshire Hathaway.

3 Dividend Aristocrat Stocks That Warren Buffett Likes the Most

Coterra Energy

Duke Energy

Mastercard

Microsoft

T-Mobile US

Visa

As the saying goes, past is not prologue. That simply means that what happened in the past doesn't fully predict what will occur in the future.

7 Stocks That Win When the Fed Hikes Interest Rates

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Why Is Johnson & Johnson (JNJ) Down 1.8% Since Last Earnings Report?

Air Products and Chemicals

Franklin Resources

Community Trust Bancorp

Emerson Electric

Leggett & Platt

Medtronic

National Fuel Gas

Northwest Natural Gas

Old Republic International

Stanley Black & Decker

Telephone and Data Systems

Universal Corp

Walgreens

Exxon Mobil

DRIP Investing lists over 800 stocks that have annually increased dividends for 5 years or more. As of July, 62 stocks have hiked their dividends annually 40 years or more. Parsed from 129 Champions, utilizing YCharts data as of 8/15/22, those 62 select-dividend stocks ranged 0.87% to 5.95% in annual yield, and ranged -17.74% to 31.143% in analyst 1-yr price.

Buy 6 August 40+ Year Dividend Growers

The company reported upbeat Q2 results last month, but it lowered its full-year outlook owing to the impact of foreign exchange, and this didn't sit well with the investors.

What's Happening With Johnson & Johnson Stock

Apple

These widely owned companies are doling out between $11.1 billion and $18.5 billion in dividend income to their shareholders each year!

These 6 Dividend Stocks Pay $83 Billion a Year, Combined, to Their Shareholders

GlaxoSmithKline

Haleon PLC

Sanofi

Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?

Potential Lawsuits Causing Zantac Manufacturers Heartburn

Procter & Gamble

If any investor has stood the test of time, it is Warren Buffett. For years, the “Oracle of Omaha” has had a rock-star-like presence in the investing world.

Warren Buffett Owns These 3 Very Safe ‘Strong Buy' Dividend Kings in Berkshire Hathaway

Courts continue to scrutinize J&J's controversial bankruptcy ploy to avoid liability MONTGOMERY, Ala. , Aug. 12, 2022 /PRNewswire/ -- Legal experts say the decision by Johnson & Johnson (NYSE: JNJ) to halt future sales and distribution of talc-based products worldwide, including its iconic Johnson's Baby Powder, points to mounting pressure on the company to resolve tens of thousands of legal claims brought by ovarian cancer and mesothelioma victims.

Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science

Johnson & Johnson is abandoning talc-based baby powder next year and instead will make it with cornstarch.

Johnson & Johnson is abandoning its talc-based baby powder

J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.

J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023

The company has faced thousands of lawsuits alleging its talcum powder caused users to develop ovarian cancer, although medical research indicates it is safe.

J&J To End Sales Of Baby Powder With Talc Globally Next Year

Company has faced lawsuits about its talc products but insists they are safe

News for Johnson & Johnson Stock (JNJ)